| BCBS Kansas City Medical Policies | Genetic Markers for Assessing Risk of Cardiovascular Disease | |
| BCBS Kansas City Medical Policies | Fasenra benralizumab | |
| BCBS Kansas City Medical Policies | Nulojix® (belatacept) | |
| BCBS Kansas City Medical Policies | Digital Health Technologies: Diagnostic Applications | |
| BCBS Kansas City Medical Policies | Therapeutic Radiopharmaceuticals for Prostate Cancer | |
| BCBS Kansas City Medical Policies | efgartigimod alfa -Vyvgart™ and Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) | |
| BCBS Kansas City Medical Policies | Betibeglogene autotemcel (Zynteglo®) (Intravenous) | |
| BCBS Kansas City Medical Policies | Percutaneous Electrical Nerve Field Stimulation for Functional Abdominal Pain Disorders | |
| BCBS Kansas City Medical Policies | Nivolumab; Relatlimab-rmbw (Opdualag) injection | |
| BCBS Kansas City Medical Policies | Inclisiran (Leqvio®) | |